Blood cancer transplant study tests blood pressure drug to prevent immune attack
NCT ID NCT02338232
First seen Apr 09, 2026 · Last updated Apr 28, 2026 · Updated 2 times
Summary
This study looked at whether the blood pressure drug telmisartan could prevent a serious complication called graft-versus-host disease (GVHD) in people receiving a stem cell transplant for blood cancers. About 32 participants were planned, but the study was stopped early. The goal was to see if the drug could reduce severe GVHD without causing dangerous low blood pressure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GVHD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
Conditions
Explore the condition pages connected to this study.